Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trialof the Gruppo Italiano per lo Studio dei Linfomi (GISL)

[1]  P. Ganly,et al.  Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Dhodapkar,et al.  Waldenstrom's macroglobulinemia: Recent advances in biology and therapy. , 2009, Clinical advances in hematology & oncology : H&O.

[3]  S. Treon.  How I treat Waldenström macroglobulinemia. , 2009, Blood.

[4]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[5]  L. Baldini,et al.  Front-Line Chemo-Immunotherapy Rituximab-FC + Rituximab Maintenance in Patients with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Preliminary Results of a Prospective Study of the Intergruppo Italiano Linfomi and Roche (ML18324). , 2008 .

[6]  K. Do,et al.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. , 2008, Blood.

[7]  H. Tilly,et al.  Epidemiology, pathology and treatment of non-follicular indolent lymphomas , 2008, Leukemia & lymphoma.

[8]  M. Gordon.  Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997 , 2008 .

[9]  P. Loehrer.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2008 .

[10]  C. Tam,et al.  Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non‐hodgkin lymphoma , 2006, Cancer.

[11]  G. Brittinger,et al.  Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. , 2005, Blood.

[12]  C. Tam,et al.  Treatment-related myelodysplasia following fludarabine combination chemotherapy. , 2006, Haematologica.

[13]  C. Tam,et al.  Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies , 2004, Cancer.

[14]  E. Schiavone,et al.  Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia , 2003, European journal of haematology.

[15]  P. Gobbi,et al.  Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  John M Bennett,et al.  Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Dimopoulos,et al.  Treatment of Waldenstrom's Macroglobulinemia with the Combination of Fludarabine and Cyclophosphamide , 2003, Leukemia & lymphoma.

[18]  W. Plunkett,et al.  DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  P. Feugier,et al.  Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. , 2001, Blood.

[20]  G. Brittinger,et al.  Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group , 2001, British journal of haematology.

[21]  H. Kantarjian,et al.  Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Cheson,et al.  Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[23]  M. Grever,et al.  Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. , 2000, Blood.

[24]  L. Gordon,et al.  Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Montserrat,et al.  In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. , 1999, Blood.

[26]  T. Lister,et al.  Immunocytoma: a retrospective analysis from St Bartholomew's Hospital-1972 to 1996. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Kittas,et al.  B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. , 1999, Seminars in hematology.

[28]  G. Salles,et al.  Indolent nonfollicular lymphomas: characteristics, treatment, and outcome. , 1999, Seminars in hematology.

[29]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Peterson,et al.  Indolent B-cell non-Hodgkin's lymphomas. , 1997, Oncology.

[31]  W. Hiddemann,et al.  Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia , 1996, The Lancet.

[32]  L. R. Hill,et al.  Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases. , 1989, Blood.

[33]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[34]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .